Search

Hemantane is an antiparkinsonian drug with pronounced analgesic and anti-inflammatory properties. The present work evaluated topical gel dosage forms based on it for analgesic activity. It was found that gel batches 070916, 080916, and 090916 exhibited analgesic activity using the formalin test in rats and diminished behavior characteristic of pain in the inflammation-mediated tonic phase of formalin-induced pain. 5% hemantane gel batch 080916 exhibited the most distinct analgesic activity because this dosage form decreased pain indicators even in the acute phase related to the effect of formalin on primary pain afferents.

Hemantane is a novel antiparkinsonian drug that is undergoing clinical trials. Hemantane in the dosage range 10 – 40 mg/kg demonstrated anti-inflammatory activity and decreased statistically significantly the intensity of the exudative reaction in an acetic-acid peritonitis model in mice. Hemantane (10 mg/kg) in a neuro-inflammation model induced by lipopolysaccharide injection in rats prevented loss of body mass, development of forepaw akinesia contralateral to the operation, and smell disturbance.